Chief Scientific Officer (potential for full-time post fundraising) – Biotechnology – Ref.: AB201911IBCSO
Our client is a pre-clinical drug discovery company developing small molecule therapeutics for the treatment of cancer. The pipeline includes first-in-class dual mechanism inhibitors AUM302 and IBL-202 along with IBL-100s PIM kinase inhibitors.
The Company is looking for an entrepreneurial-minded consultant to work with the CEO to formulate and implement a plan that will strengthen the management team and finance the business going forward.
Post funding there will be the potential for full time. As an emerging cancer biotech, and given the importance of this position, the remuneration package for the full-time role will include equity participation.
Pending the creation of the full-time role the Consultant are required to fulfil the following role on an interim basis.
Responsibilities & Requirements:
- Thorough knowledge of cancer biology, kinase signalling pathways
- Knowledge of PI3K and related pathways a bonus
- Managing licencing opportunities, interacting and influencing key stakeholders.
- financially savvy with high levels of business acumen.
The exact duties and the nature of each role will be subject to discussion with the CEO.